A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae

Journal of Infectious Diseases

Volumn 177, Issue 6, 1998, Pages 1573-1581

  Prammananan, Therdsak ^b   Sander, Peter ^b   Brown, Barbara A ^b   Frischkorn, Klaus ^b   Onyi, Grace O ^b   Zhang, Yansheng ^b   Böttger, Erik C ^b   Wallace Jr , Richard J ^a  

^a UNIVERSITY OF TEXAS AT TYLER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN; KANAMYCIN; NEOMYCIN; RNA 16S; STREPTOMYCIN; TOBRAMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM CHELONEI; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; RIBOSOME SUBUNIT;

EID: 0031802176     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515328     Document Type: Article

References (16)

1. Streptomycin in Tuberculosis Trials Committee. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948;2:769-82.
2. Wallace RJ Jr, Dunbar D, Brown BA, et al. Rifampin-resistant Mycobacterium kansasii. Clin Infect Dis 1994;18:736-43.
3. Simor AE, Salit IE, Vellend H. The role of Mycobacterium xenopi in human disease. Am Rev Respir Dis 1984;129:435-8.
4. Wallace RJ Jr, Cook JL, Glassroth J, Griffith DE, Olivier KM, Gordin F. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. American Thoracic Society Statement. Am Rev Respir Crit Care Med 1997;156(suppl):S1-25.
5. Valero G, Peters J, Jorgensen JH, Graybill JR. Clinical isolates of Mycobacterium simiae in San Antonio, Texas. Am J Respir Crit Care Med 1995;152:1555-7.
6. Meier A, Kirschner P, Bange FC, Vogel U, Böttger EC. Genetic alterations in streptomycin-resistant Mycobacterium tuberculosis: mapping of mutations conferring resistance. Antimicrob Agents Chemother 1994;38:228-33.
7. Meier A, Sander P, Schaper KJ, Scholz M, Böttger EC. Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996;40:2452-4.
8. Honoré N, Cole ST. Streptomycin resistance in mycobacteria. Antimicrob Agents Chemother 1994;38:238-42.
9. Finken M, Kirschner P, Meier A, Wrede A, Böttger EC. Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudo knot. Mol Microbiol 1993;9:1239-46.
10. Sreevatsan S, Pan X, Stockbauer KE, Williams DL, Kreiswirth BN, Musser JM. Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic localities. Antimicrob Agents Chemother 1996;40:1024-6.
11. Böttger EC. Resistance to drugs targeting protein synthesis in mycobacteria. Trends Microbiol 1994;2:416-21.
12. Cooksey RC, Morlock GP, McQueen A, Glickman SE, Crawford JT. Characterization of streptomycin resistance mechanisms among Mycobacterium tuberculosis isolates from patient in New York City. Antimicrob Agents Chemother 1996;40:1186-8.
13. Allen BW, Mitchison DA, Chan YC, Yet WW, Allan WGL, Girling DJ. Amikacin in the treatment of pulmonary tuberculosis. Tubercle 1983;64:111-8.
14. Dalovisio JR, Pankey GA, Wallace RJ Jr, Jones DB. Clinical usefulness of amikacin and doxycycline in the treatment of human infection of Mycobacterium fortuitum and Mycobacterium chelonei. Rev Infect Dis 1981;3:1068-74.
15. Wallace RJ Jr, Swenson JM, Silcox VA, Bullen MG. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei based on in vitro susceptibilities. J Infect Dis 1985;152:500-14.
16. Swenson JM, Wallace RJ Jr, Silcox VA, Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 1985;28:807-11.